Slingshot members are tracking this event:

FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gvhd, Acute Graft-versus-host Disease, Jakafi, Ruxolitinib, Acute Graft-versus-host Disease